<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818178</url>
  </required_header>
  <id_info>
    <org_study_id>18-002520</org_study_id>
    <secondary_id>5R01DK045343-27</secondary_id>
    <nct_id>NCT03818178</nct_id>
  </id_info>
  <brief_title>Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids</brief_title>
  <official_title>Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes
      (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular
      fatty acid trafficking is responsible for muscle insulin resistance, although it has been
      shown that raising FFA with Intralipid can cause muscle insulin resistance within 4 hours.
      The investigators do not understand to what extent the incorporation of FFA into ceramides or
      diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. The investigators
      propose to alter the profile and concentrations of FFA of healthy, non-obese adults using an
      overnight, intra-duodenal palm oil infusion vs. an overnight intra-duodenal Intralipid
      infusion (both compared to saline control). The investigators will compare the muscle FFA
      storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking,
      activation of the insulin signaling pathway and glucose disposal rates, providing the first
      measure of how different FFA profiles alter muscle FFA trafficking and insulin action at the
      whole body and cellular/molecular levels. By identifying which steps in the insulin signaling
      pathway are most affected, the investigators will determine the site-specific effect of
      ceramides and/or DG on different degrees of insulin resistance.

      Hypothesis 1: Palm oil infusion will result in abnormal FFA trafficking into
      intra-myocellular ceramides and abnormal insulin signaling.

      Hypothesis 2: Intralipid infusion will result in abnormal FFA trafficking into
      intra-myocellular saturated DG and abnormal insulin signaling.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fatty acid enrichment of intramyocellular signaling molecules before and after a euglycemic, hyperinsulinemic clamp</measure>
    <time_frame>18 hours</time_frame>
    <description>The study involves the use of a hyperinsulinemic, euglycemic clamp to compare fatty acid enrichments in intramyocellular signaling molecules. The first half of the study will be the &quot;pre-clamp&quot; stage. During this stage, volunteers will receive an intravenous infusion of C13-labelled palmitate as a tracer in order for enrichment calculations to be performed pre-clamp. One muscle biopsy will be obtained to measure fatty acid enrichment within intramyocellular ceramides, diacylglycerols, long-chain acylcarnitines, and intramyocellular triglycerides. The insulin clamp will then commence, and volunteers will simultaneously receive an intravenous infusion of a second tracer, D-9 palmitate. This tracer will allow us to calculate enrichments during the insulin clamp stage of the study. A second muscle biopsy will be performed at the end of the insulin clamp, and similar enrichment calculations will be performed.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Intralipid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Palm Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.</description>
    <arm_group_label>Intralipid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Palm Oil Emulsion</intervention_name>
    <description>Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.</description>
    <arm_group_label>Palm Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>All participants will serve as their own controls with a saline infusion study day.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and Men (Women premenopausal)

          -  BMI 18-27

          -  Weight stable

          -  Not pregnant/nursing

        Exclusion Criteria:

          -  Ischemic heart disease

          -  Atherosclerotic valvular disease

          -  Smokers (&gt; 20 cigarettes per week)

          -  Bilateral oophorectomy

          -  Concomitant use of medications that can alter serum lipid profile (high dose fish oil,
             statins, niacin, fibrates, thiazolinediones, beta-blockers, atypical antipsychotics)

          -  Lidocaine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah C Wolhart, BSN</last_name>
    <phone>507-255-6940</phone>
    <email>wolhart.sarah@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela A Reich, SC</last_name>
      <phone>507-255-6062</phone>
      <email>reich.pamela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael D. Jensen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

